Meeting
2019 ASCO Annual Meeting
Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).
Authors
Lauren Averett Byers
Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX
Lauren Averett Byers , Alberto Chiappori , Marie-Anne Damiette Smit
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03392064
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS8576)
DOI
10.1200/JCO.2019.37.15_suppl.TPS8576
Abstract #
TPS8576
Poster Bd #
328b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).
First Author: Frederick L. Locke
Poster
2022 ASCO Annual Meeting
KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).
First Author: Loretta J. Nastoupil
Poster
2020 ASCO Virtual Scientific Program
Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).
First Author: Taofeek Kunle Owonikoko
Poster
2019 ASCO Annual Meeting
Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).
First Author: Hiroaki Akamatsu